CJC-1295

Research

CJC-1295 (with/without DAC)

Category
Growth Hormone
Aliases
DAC:GRF, Modified GRF 1-29
Administration
Subcutaneous injection

Research and regulatory

Development stage

Phase I/II completed — discontinued by ConjuChem.

Legal and regulatory

Unscheduled research compound.

Side effects

Water retention, tingling, hunger, fatigue